Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Combination Therapy in Geriatric Population with Cancer
share announcement

Combination Therapy in Geriatric Population with Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 May 2024 | Viewed by 2416

Special Issue Editor

Prof. Dr. Lore Decoster

E-Mail Website
Guest Editor
Department of Medical Oncology, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium
Interests: geriatric oncology; lung cancer; immunotherapy resistance

Special Issue Information

Dear Colleagues,

Cancer has a higher chance of developing with age. The increasing life expectancy of the population will, therefore, result in an increasing number of older patients with cancer. Treatment decisions in the older population are often challenging for different reasons. Firstly, the older population is more vulnerable in terms of frailty, organ reserve, co-morbidities, polypharmacy and expectations. Secondly, registration trials predominantly include young and fit patients due to the stringent in- and exclusion criteria, resulting in a lack of data about those outside of these requirements.  In addition, the main endpoints of these trials are often survival-related (either overall survival or progression-free survival). Consequently, there is a lack of knowledge on the efficacy, safety, pharmacodynamics and pharmacokinetics of treatments in older patients. Data on the effect of treatments on daily functioning and quality of life in this older population are, therefore, scarce.

In this Special Issue of Cancers, we welcome original research articles or comprehensive review articles focusing on different treatments (including surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy and combinations) for older patients with cancer, regardless of cancer type.

Prof. Dr. Lore Decoster
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • older patients with cancer
  • surgery
  • radiotherapy
  • chemotherapy
  • immunotherapy
  • targeted therapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 581 KiB  
Article
Predicting Risk of Severe Toxicity and Early Death in Older Adult Patients Treated with Chemotherapy
by Jaime Feliu, Ana Belén Custodio, Alvaro Pinto-Marín, Oliver Higuera, Miriam Pérez-González, Laura del Pino, Leticia Ruiz-Jiménez, Darío Sánchez-Cabero, Isabel Viera, Ana Jurado and Enrique Espinosa
Cancers 2023, 15(18), 4670; https://doi.org/10.3390/cancers15184670 - 21 Sep 2023
Viewed by 1064
Abstract
Background: Determining the risk of grade 3–5 toxicity and early death (ED) is important to plan chemotherapy in older adult patients with cancer. Our objective was to identify factors predicting these complications at the time of treatment initiation. Methods: 234 patients aged ≥70 [...] Read more.
Background: Determining the risk of grade 3–5 toxicity and early death (ED) is important to plan chemotherapy in older adult patients with cancer. Our objective was to identify factors predicting these complications at the time of treatment initiation. Methods: 234 patients aged ≥70 were subjected to a geriatric assessment and variables related to the tumor and the treatment were also collected. Logistic regression multivariable analysis was used to relate these factors with the appearance of grade 3–5 toxicity and ED. Predictive scores for both toxicity and ED were then developed. Results: Factors related to grade 3–5 toxicity were hemoglobin, MAX2 index, ADL, and the CONUT score. Factors related to ED were tumor stage and the GNRI score. Two predictive scores were developed using these variables. ROC curves for the prediction of toxicity and ED were 0.71 (95% CI: 0.64–0.78) and 0.73 (95% CI: 0.68–0.79), respectively. Conclusions: Two simple and reliable scores were developed to predict grade 3–5 toxicity and ED in older adult patients with cancer. This may be helpful in treatment planning. Full article
(This article belongs to the Special Issue Combination Therapy in Geriatric Population with Cancer)
►▼ Show Figures

Figure 1

11 pages, 1609 KiB  
Article
Adjuvant Chemotherapy in Older Patients with Gastric Cancer: A Population-Based Cohort Study
by Wing-Lok Chan, Xiaodong Liu, Carlos King-Ho Wong, Michael Siu-Nam Wong, Ian Yu-Hong Wong, Ka-On Lam, Bryan Ho-Kwan Yun, Emina Edith Cheung, Rosa Pui-Ying Tse, Fion Chan, Simon Law and Dora Kwong
Cancers 2023, 15(15), 3768; https://doi.org/10.3390/cancers15153768 - 25 Jul 2023
Viewed by 1012
Abstract
(1) Background: The effectiveness of adjuvant chemotherapy in older patients with gastric cancer after D2-gastrectomy is unclear. This study investigated the efficacy of adjuvant chemotherapy in elderly patients with stage II/III gastric cancer. (2) Methods: A real-world population-based retrospective cohort of patients aged [...] Read more.
(1) Background: The effectiveness of adjuvant chemotherapy in older patients with gastric cancer after D2-gastrectomy is unclear. This study investigated the efficacy of adjuvant chemotherapy in elderly patients with stage II/III gastric cancer. (2) Methods: A real-world population-based retrospective cohort of patients aged ≥65 with stage II/III gastric cancer (n = 2616; median age: 73.5; 12.2% aged >80 years) treated between 1 January 1997 and 31 December 2020 were included. All data was retrieved from the Hong Kong Hospital Authority Clinical Management System (CMS). Clinical characteristics of those patients with and without adjuvant chemotherapy treatment were balanced after propensity score matching (PSM). In total, 732 patients treated with adjuvant chemotherapy were matched with 732 patients treated with surgery alone. Hazard ratios (HRs) estimated via Cox proportional hazards regression models were used to compare the overall survival (OS) and cancer-specific survival (CSS) of the two patient groups. (3) Results: Adjuvant chemotherapy was associated with better OS (37 vs. 25 months; HR: 0.80; 95% CI: 0.75–0.84; p < 0.001) than surgery alone. The OS benefit was observed in both the 65–80 (44 vs. 27 months; HR: 0.79; 95% CI: 0.74–0.84; p < 0.001) and >80 (14 vs. 11 months; HR: 0.82; 95% CI: 0.71–0.96; p < 0.001) age groups. A better CSS was observed in patients who received adjuvant chemotherapy than those who only had surgery (5-year CSS: 64.1% vs. 61.1%, HR: 0.85; 95% CI: 0.79–0.93; p < 0.001). (4) Conclusions: adjuvant chemotherapy significantly improved OS and CSS in older patients with stage II/III gastric cancer. Full article
(This article belongs to the Special Issue Combination Therapy in Geriatric Population with Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop